Qdenga® - A promising dengue fever vaccine; can it be recommended to non-immune travelers?

• Published in: Travel Medicine and Infectious Disease
• Main Authors: Martin Angelin, Jan Sjölin, Fredrik Kahn, Anna Ljunghill Hedberg, Anja Rosdahl, Paul Skorup, Simon Werner, Susanne Woxenius, Helena H. Askling
• Format: Article in Journal/Newspaper
• Language: English
• Published: Elsevier 2023
• Subjects: Arctic medicine. Tropical medicine; RC955-962; Infectious and parasitic diseases; RC109-216; Arctic
• Online Access: https://doi.org/10.1016/j.tmaid.2023.102598; https://doaj.org/article/f875f822f19a4008ac132eaff93b73b4

Qdenga® has been approved by the European Medicines Agency (EMA) for individuals > 4 years of age and for use according to national recommendations. The vaccine shows high efficacy against virologically confirmed dengue and severe dengue in clinical studies on 4–16-year old's living in endemic areas. For individuals 16–60 years old only serological data exists and there is no data for individuals > 60 years. Its use as a travel vaccine is still unclear. We present the studies behind the approval and the recommendations for travelers as issued by the Swedish Society for Infectious Diseases Physicians.